EndoPredict® is the only second generation breast cancer prognostic test validated for premenopausal AND postmenopausal women with early-stage breast cancer that is ER positive, HER2 negative, node negative or positive1-7 – and the only second generation test with level of evidence 1A data.8,9
EndoPredict is the most accurate prognostic test to guide early treatment decisions, providing an individual risk for distant recurrence ten years after breast cancer diagnosis. This crucial information helps avoid under and over treatment in all patient subgroups.10
If you are a patient, please ask your doctor if the EndoPredict test is right for you, or visit our patient homepage for more information.
In all validation studies of ER positive, HER2 negative, node positive and node negative patients, EndoPredict identified a large low-risk group for recurrent breast cancer after 10 years, with a recurrence risk of less than 10%, regardless whether the patients were pre- or postmenopausal.1-7
The homogenous (solely ER positive, HER2 negative) cohorts used are one reason for the test’s stronger performance compared to tests that included HER2 positive patients in their training cohorts. The score and the cut-off value are consistent in all studies and have never changed.
Compared to risk stratification using only clinical parameters or other gene expression tests, EndoPredict identifies a large group of true low-risk breast cancer patients who could avoid chemotherapy.4,7,10 Learn more about this comparison study here.
In node positive patients, EndoPredict was one of the two signatures that identified patients with true low risk of distant recurrence (<10%) at 10 years.
Learn more about EndoPredict in node positive patients.
EndoPredict® is backed by robust evidence, including Level of Evidence 1A, as recommended by ESMO guidelines.13 It is the only second-generation breast cancer recurrence test with level of evidence 1A data. Initial results from a randomized controlled prospective phase III study (UNIRAD) released at SABCS 2021 prospectively confirm the validation studies.8
Ongoing research of the Technical University of Munich and the University Hospital Charité in Berlin that was already published in parts at past conferences provides prospective real-world outcome data, further solidifying EndoPredict’s validation and clinical utility. (TUM, Charite). A prospective French registry (SiMoSein) with more than 4,700 patients presented as a poster at the Annual ESMO Meeting 2021 emphasizes the clinical need for gene expression testing to avoid over and under-treatment.11
EndoPredict is the most accurate prognostic test with two clear risk groups across 10 years compared to first generation AND second generation breast cancer recurrence tests.10
Studies show that regardless of nodal status, EndoPredict detects premenopausal patients who are true low-risk that may safely avoid chemotherapy.2,12
EndoPredict illuminates the right treatment pathway for every woman, regardless of nodal status or number of positive lymph nodes.
The EndoPredict animated app can show you how various gene activities in the tumor influence the prognosis and how the molecular fingerprint and tumor size and nodal status contribute to the final EndoPredict result.
EndoPredict Breast Cancer Prognostic Test is available to order by clinicians via numerous local labs in your country or outside of the EU also via Myriad Genetics’ central laboratory in Salt Lake City, USA.